<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I;V1176F literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I;V1176F</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.036" class="lit_link">Hoffman et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.<br/> (<a href="https://doi.org/10.1101/2021.05.11.21256908" class="lit_link">Mendes-Correa et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. <br/> [paper does not detail the P.1 variants used, using the most popular as a stand in] (<a href="https://doi.org/10.1101/2021.03.31.437925" class="lit_link">McCallum et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab.<br/>Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.036" class="lit_link">Hoffman et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines.<br/>Cell fusion proficiency was slight impaired. (<a href="https://doi.org/10.1016/j.cell.2021.03.036" class="lit_link">Hoffman et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose.<br/>Cell fusion proficiency was slight impaired. (<a href="https://doi.org/10.1016/j.cell.2021.03.036" class="lit_link">Hoffman et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ or CD8+ cell count effect for P.1 by Activation Induced Marker (AIM) assay (cellular immunity measurement). No signficant change in IF-gamma or IL-5 spot  forming cell counts were observed.<br/> (<a href="https://doi.org/10.1101/2021.02.27.433180" class="lit_link">Tarke et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.<br/> (<a href="https://doi.org/10.1101/2021.06.28.449914" class="lit_link">Choi et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
